JP2016512216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512216A5 JP2016512216A5 JP2015562236A JP2015562236A JP2016512216A5 JP 2016512216 A5 JP2016512216 A5 JP 2016512216A5 JP 2015562236 A JP2015562236 A JP 2015562236A JP 2015562236 A JP2015562236 A JP 2015562236A JP 2016512216 A5 JP2016512216 A5 JP 2016512216A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- antigen
- monoclonal antibody
- main peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 238000005194 fractionation Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 238000004255 ion exchange chromatography Methods 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 238000011098 chromatofocusing Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1352360 | 2013-03-15 | ||
| FR1352360A FR3003171B1 (fr) | 2013-03-15 | 2013-03-15 | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
| PCT/EP2014/055179 WO2014140322A1 (fr) | 2013-03-15 | 2014-03-14 | Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512216A JP2016512216A (ja) | 2016-04-25 |
| JP2016512216A5 true JP2016512216A5 (enExample) | 2017-04-06 |
Family
ID=48771615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562236A Pending JP2016512216A (ja) | 2013-03-15 | 2014-03-14 | 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160046722A1 (enExample) |
| EP (1) | EP2968533A1 (enExample) |
| JP (1) | JP2016512216A (enExample) |
| KR (1) | KR20150132522A (enExample) |
| CN (1) | CN105163758B (enExample) |
| AU (1) | AU2014230134A1 (enExample) |
| BR (1) | BR112015023209A8 (enExample) |
| CA (1) | CA2907358A1 (enExample) |
| FR (1) | FR3003171B1 (enExample) |
| MX (1) | MX2015012812A (enExample) |
| WO (1) | WO2014140322A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6454547B2 (ja) | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
| DK3451820T3 (da) | 2016-05-04 | 2021-01-18 | Delaval Holding Ab | Kassette og konnektor til en pattekop samt pattekop, der omfatter kassetten og konnektoren |
| FR3053688B1 (fr) * | 2016-07-06 | 2026-05-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| SG11202107941TA (en) | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
| US20200369720A1 (en) * | 2019-05-23 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Characterization of domain-specific charge variants of antibodies |
| WO2021057726A1 (zh) * | 2019-09-23 | 2021-04-01 | 南开大学 | 利用哺乳动物展示筛选FcγR特异性结合Fc |
| PL4401842T3 (pl) | 2021-09-16 | 2025-11-24 | Aboleris Pharma | Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania |
| CN114236010A (zh) * | 2021-12-18 | 2022-03-25 | 苏州莱奥生物技术有限公司 | 一种生物活性药物的药代动力学分析方法 |
| CN115073548A (zh) * | 2022-08-01 | 2022-09-20 | 上海蓝析生物技术有限公司 | 一种用于重组蛋白药物电荷异构体制备的缓冲体系 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL209392B1 (pl) * | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| EP1553975B8 (en) * | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| CA2512729C (en) * | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| FR2861078B1 (fr) * | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| JP6454547B2 (ja) * | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
-
2013
- 2013-03-15 FR FR1352360A patent/FR3003171B1/fr not_active Expired - Fee Related
-
2014
- 2014-03-14 JP JP2015562236A patent/JP2016512216A/ja active Pending
- 2014-03-14 CA CA2907358A patent/CA2907358A1/fr not_active Abandoned
- 2014-03-14 AU AU2014230134A patent/AU2014230134A1/en not_active Abandoned
- 2014-03-14 US US14/776,725 patent/US20160046722A1/en not_active Abandoned
- 2014-03-14 CN CN201480024699.3A patent/CN105163758B/zh not_active Expired - Fee Related
- 2014-03-14 BR BR112015023209A patent/BR112015023209A8/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020157029822A patent/KR20150132522A/ko not_active Withdrawn
- 2014-03-14 MX MX2015012812A patent/MX2015012812A/es unknown
- 2014-03-14 EP EP14709977.4A patent/EP2968533A1/fr not_active Withdrawn
- 2014-03-14 WO PCT/EP2014/055179 patent/WO2014140322A1/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512216A5 (enExample) | ||
| PH12019502561A1 (en) | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| PE20221789A1 (es) | Composiciones de proteina anti-vegf y metodos para producir la misma | |
| MY205758A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| NZ734803A (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| MX2022001830A (es) | Anticuerpos terapeuticos y sus usos. | |
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| JOP20190002A1 (ar) | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| MX2021005193A (es) | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. | |
| JP2017518258A5 (enExample) | ||
| BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| MY206214A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. | |
| MX2021003756A (es) | Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos. | |
| EA201891301A1 (ru) | Антитела против dr5 и способы их применения | |
| EA201992512A1 (ru) | Антигенсвязывающие белки, связывающие trem2, и пути их применения | |
| NZ780754A (en) | Antigen-binding proteins that activate the leptin receptor | |
| NZ780754B2 (en) | Antigen-binding proteins that activate the leptin receptor | |
| BRPI0716611A2 (pt) | anticorpo monoclonal quimérico, ácido nucléico isolado, célula isolada, composição farmacêutica, e, método para tratar uma doença ou distúrbio |